| 于澜,徐缨龙,李明,等.肝动脉化疗栓塞术序贯甲磺酸阿帕替尼治疗晚期肝门部胆管癌的有效性和安全性[J].安徽医药,2023,27(8):1685-1688. |
| 肝动脉化疗栓塞术序贯甲磺酸阿帕替尼治疗晚期肝门部胆管癌的有效性和安全性 |
| Efficacy and safety of transcatheter arterial chemoembolization sequential apatinib mesylate in the treatment of advanced hilar cholangiocarcinoma |
| |
| DOI：10.3969/j.issn.1009-6469.2023.08.043 |
| 中文关键词: 胆管肿瘤 肝动脉化疗栓塞术 甲磺酸阿帕替尼 有效性 安全性 |
| 英文关键词: Bile duct neoplasms Transcatheter arterial chemoembolization Apatinib mesylate Effectiveness Safety |
| 基金项目: |
|
| 摘要点击次数: 1015 |
| 全文下载次数: 591 |
| 中文摘要: |
| 目的探讨肝动脉化疗栓塞术( TACE)序贯甲磺酸阿帕替尼治疗晚期肝门部胆管癌( HCCA)的有效性和安全性。方法回顾性分析成都市第三人民医院 2017年 6月至 2020年 6月收治的 50例晚期 HCCA病人的临床资料，依据治疗方案的不同分为两组， A组( n=24)给予经皮肝胆道支架置入术， B组( n=26)在经皮肝胆道支架置入术后给予 TACE序贯甲磺酸阿帕替尼治疗。对比两组疗效、生存情况、不良反应，检测血清 γ-谷氨酰转肽酶( γ-GT)、总胆红素( TBIL)、丙氨酸氨基转移酶( ALT)水平。结果 B组客观缓解率 61.54%高于 A组 33.33%(P<0.05)。治疗后两组血清 γ-GT、TBIL、ALT水平均低于治疗前( P<0.05)且治疗后 B组血清 γ-GT、TBIL、ALT水平均低于 A组( P<0.05)。 B组 6个月生存率、 1年生存率均高于 A组( P<0.05)。两组组良反应发生率比较差异无统计学意义( P>0.05)。结论 TACE序贯甲磺酸阿帕替尼治疗晚期 HCCA疗效确切，能延间不，长病人生存时间，利于改善病人肝功能，且未增加不良反应发生。 |
| 英文摘要: |
| Objective To investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) sequential apatinibmesylate in the treatment of advanced hilar cholangiocarcinoma (HCCA).Methods The clinical data of 50 patients with advanced HCCA admitted to Chengdu Third People's Hospital from June 2017 to June 2020 were retrospectively analyzed. They were assigned intotwo groups according to the different treatment plans. Group A (n=24) received percutaneous hepatobiliary stent implantation, and group B (n=26) was treated with TACE sequential apatinib mesylate after percutaneous hepatobiliary stent implantation. The efficacy,survival, and adverse reactions of the two groups were compared, and the serum γ -glutamyl transpeptidase (γ -GT), total bilirubin (TBIL), and alanine aminotransferase (ALT) levels were detected.Results The objective response rate of group B was 61.54%, which was higher than that of group A 33.33% (P<0.05). After treatment, the levels of serum γ-GT, TBIL, and ALT in the two groups were low er than those before treatment (P<0.05), and after treatment, the levels of serum γ-GT, TBIL, and ALT in group B were lower than those in group A (P<0.05). The 6-month survival rate and 1-year survival rate of group B were higher than those of group A (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion TACE sequential apatinib mesylate has a definite effect in the treatment of advanced HCCA, it can prolong the survival time of patients, improve their liverfunction, without increasing the occurrence of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
